G01N 2333/495
Transforming growth factor [tgf]
Official title: Transforming growth factor [TGF]
G01N2333/495 (Transforming growth factor [tgf]) appears on 182 US grants and 325 published applications in this corpus.
Search patents in G01N- Granted patents
- 182
- Published applications
- 325
- Assignees
- 190
- Inventors
- 598
- Latest grant
- 5 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 2 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 3 | 0 |
| 1998 | 3 | 0 |
| 1999 | 2 | 0 |
| 2000 | 6 | 0 |
| 2001 | 2 | 2 |
| 2002 | 10 | 7 |
| 2003 | 3 | 11 |
| 2004 | 6 | 7 |
| 2005 | 5 | 7 |
| 2006 | 3 | 11 |
| 2007 | 3 | 7 |
| 2008 | 4 | 5 |
| 2009 | 4 | 9 |
| 2010 | 5 | 24 |
| 2011 | 10 | 12 |
| 2012 | 9 | 15 |
| 2013 | 3 | 11 |
| 2014 | 9 | 12 |
| 2015 | 3 | 16 |
| 2016 | 8 | 17 |
| 2017 | 7 | 20 |
| 2018 | 8 | 19 |
| 2019 | 9 | 14 |
| 2020 | 9 | 23 |
| 2021 | 8 | 18 |
| 2022 | 11 | 12 |
| 2023 | 6 | 12 |
| 2024 | 7 | 13 |
| 2025 | 7 | 11 |
| 2026 | 5 | 10 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Product quality attribute measurement5 May 2026US 12,618,040 B2Genzyme Corporation
- Biomarkers of renal injury14 Apr 2026US 12,601,746 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Compositions and methods for growth factor modulation17 Mar 2026US 12,577,296 B2Scholar Rock, Inc.
- Application of TGF-B inhibitor in inducing neural stem cells and organoid formation10 Feb 2026US 12,545,892 B2Iregene Therapeutics Ltd
- Biomarkers for risk prediction of mortality6 Jan 2026US 12,517,139 B2Roche Diagnostics Operations, Inc.
- Biomarkers for neurodegenerative disease17 Sep 2026US 2026/0272976 A1Neuvivo, Inc.
- Cf48 kidney injury biomarker and use thereof in kidney injury treatment drug20 Aug 2026US 2026/0243780 A1Guangzhou Kangrun Biotechnology Co., Ltd.
- Diagnosis and treatment of neurogenic heterotopic ossification6 Aug 2026US 2026/0227386 A1FundacióN PúBlica Galega Instituto De InvestigacióN Sanitaria De Santiago De Compostela
- Method for selecting stem cells with enhanced cartilage differentiation capability and cell therapy product comprising same23 Jul 2026US 2026/0209709 A1
- Prophylactic or therapeutic agent for acute kidney injury induced by anticancer agent9 Jul 2026US 2026/0191823 A1Kyowa Hakko Bio Co., Ltd.
Most cited
By later US patents
- Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same147US 6,656,475 B1The Johns Hopkins University School of Medicine · 2003
- Compounds and therapies for the prevention of vascular and non-vascular pathologies146US 6,117,911 ANeoRx Corporation · 2000
- Transgenic non-human animals expressing a truncated activintype II receptor117US 6,891,082 B2The Johns Hopkins University School of Medicine · 2005
- Methods to identify growth differentiation factor (GDF) binding proteins101US 6,696,260 B1The Johns Hopkins University School of Medicine · 2004
- Antibodies associated with alterations in bone density88US 6,803,453 B1Darwin Discovery, Ltd. · 2004